Cargando…

The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin

INTRODUCTION: Between 2010 and 2012, the US Food and Drug Administration and Health Canada issued warnings to healthcare professionals emphasizing the increased risk of muscle problems with high-dose simvastatin. OBJECTIVE: To measure the impact of the Health Canada safety warning regarding dose-dep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anand, Kanika, Sketris, Ingrid, Zhang, Ying, Levy, Adrian, Gamble, John-Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684045/ https://www.ncbi.nlm.nih.gov/pubmed/28956294 http://dx.doi.org/10.1007/s40801-017-0116-7

Ejemplares similares

The Effects of the FDA Warning on the Use of Droperidol by U.S. Emergency Physicians
por: Richards, John R., et al.
Publicado: (2003)

Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing
por: Yim, Seon-Hee, et al.
Publicado: (2014)

Institutional response to FDA warning on aprotinin and impact on outcomes
por: Swaminathan, M, et al.
Publicado: (2009)

855. Impact of FDA Black Box Warning on Fluoroquinolone and Alternative Antibiotic Use in Southeastern US Hospitals
por: Yarrington, Michael, et al.
Publicado: (2018)

Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes
por: DiNicolantonio, James J., et al.
Publicado: (2013)

Measuring the impact of pharmacoepidemiologic research using altmetrics: A case study of a CNODES drug‐safety article
por: Gamble, J.M., et al.
Publicado: (2018)

New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist
por: Koshak, Emad A.
Publicado: (2010)

An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
por: Chaloupka, Frank J, et al.
Publicado: (2015)

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021)

Public Perceptions of Breast Implant Complications and the FDA Boxed Warning on Implants
por: Hyland, Colby J., et al.
Publicado: (2022)

FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force
por: French, Jacqueline A., et al.
Publicado: (2021)

FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory From the Ad Hoc ILAE/AES Task Force
por: French, Jacqueline A., et al.
Publicado: (2021)

Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs
por: Ahuja, Vishal, et al.
Publicado: (2015)

1863. Antibiotic Prescribing Before and After an FDA Boxed Warning on Fluoroquinolones in 2016
por: Willis, Zachary, et al.
Publicado: (2018)

Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning
por: Cook, Benjamin L., et al.
Publicado: (2019)

Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters
por: Bramstedt, Katrina A.
Publicado: (2020)

Trends and uptake of new formulations of controlled‐release oxycodone in Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022
por: Dmour, Isra
Publicado: (2022)

Link between FDA antidepressant warnings and increased suicide attempts in young people is questionable
por: Olfson, Mark, et al.
Publicado: (2014)

338. ChatGPT Conveys Incorrect Information about the FDA’s Antibiotic Boxed Warnings
por: Linfield, Rebecca, et al.
Publicado: (2023)

An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims
por: Chatterjee, Satabdi, et al.
Publicado: (2012)

Animal‐to‐Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule
por: Nagy, CF, et al.
Publicado: (2016)

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
por: Tarantino, Nicola, et al.
Publicado: (2017)

The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?
por: Fornaro, Michele, et al.
Publicado: (2019)

FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010–2020
por: Rathore, Anurag S., et al.
Publicado: (2022)

The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
por: Yoon, Hye Eun, et al.
Publicado: (2009)

Population prevalence of high dose paracetamol in dispensed paracetamol/opioid prescription combinations: an observational study
por: Clark, Roderick, et al.
Publicado: (2012)

Policy Coherence in US Tobacco Control: Beyond FDA Regulation
por: Yang, Joshua S., et al.
Publicado: (2009)

The menacing assaults on science, FDA, CDC, and health of the US public
por: Alter, Scott M., et al.
Publicado: (2020)

No two classes of biosimilars: Urgent advice to the US Congress and the FDA
por: Niazi, Sarfaraz K.
Publicado: (2022)

Understanding Vaccine Safety and the Roles of the FDA and the CDC
por: Meissner, H. Cody
Publicado: (2022)

Drug information resources used by nurse practitioners and collaborating physicians at the point of care in Nova Scotia, Canada: a survey and review of the literature
por: Murphy, Andrea L, et al.
Publicado: (2006)

The relationship between type of drug therapy and blood glucose self-monitoring test strips claimed by beneficiaries of the Seniors' Pharmacare Program in Nova Scotia, Canada
por: Sanyal, Chiranjeev, et al.
Publicado: (2008)

Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)
por: Bardini, Gianluca, et al.
Publicado: (2010)

Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study
por: Lu, Christine Y, et al.
Publicado: (2014)

Could the vaginal wall sling still have a role after FDA’s warning? the functional outcomes at 20 years
por: Illiano, Ester, et al.
Publicado: (2022)

The Safety Profile of FDA-Approved Epithelium-Off Corneal Cross-Linking in a US Community-Based Healthcare System
por: Ang, Michael J, et al.
Publicado: (2022)

The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study
por: Major, Jacqueline M., et al.
Publicado: (2018)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

Young Adults’ Perceptions of Cigarette Warning Labels in the United States and Canada
por: O’Hegarty, Michelle, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_jc9trfidphjsf96mcporqprd0o